Novel Mode of Action of Tylophorine Analogs as Antitumor Compounds

Cancer Research

Volumn 64, Issue 2, 2004, Pages 678-688

  Gao, Wenli ^a   Lam, Wing ^a   Zhong, Sanbao ^b   Kaczmarek, Conrad ^b   Baker, David C ^b   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CYCLIC AMP; DCB 3500; DCB 3501; DCB 3502; DCB 3503; ETOPOSIDE; HYDROXYUREA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR AP 1; TYLOPHORINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN HEPG2; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SENSITIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; GENES, REPORTER; HUMANS; INDOLIZINES; KB CELLS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; PHENANTHRENES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION; TUMOR STEM CELL ASSAY;

EID: 1642475128     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1904     Document Type: Article

References (40)

1. Li, Z., Zhong, J., and Huang, R. Isolation, total synthesis and biological activity of phenanthroindolizidine and phenanthroquinolizidine alkaloids. Synthesis, 16: 2365-2378, 2001.
2. Donaldson, G. R., Atkinson, M. R., and Murray, A. W. Inhibition of protein synthesis in Ehrlich ascites-tumour cells by the phenanthrene alkaloids tylophorine, tylocrebrine and cryptopleurine. Biochem. Biophys. Res. Commun., 31: 104-109, 1968.
3. Rao, K. V., Wilson, R. A., and Cummings, B. Alkaloids of tylophora. III. New alkaloids of Tylophora indica (Burm) Merrill and Tylophora dalzellii Hook. f. J. Pharm. Sci., 60: 1725-1726, 1971.
4. Rao, K. N., Bhattacharya, R. K., and Venkatachalam, S. R. Inhibition of thymidylate synthase and cell growth by the phenanthroindolizidine alkaloids pergularinine and tylophorinidine. Chem. Biol. Interact., 106: 201-212, 1997.
5. Rao, K. N., and Venkatachalam, S. R. Inhibition of dihydrofolate reductase and cell growth activity by the phenanthroindolizidine alkaloids pergularinine and tylophorinidine: the in vitro cytotoxicity of these plant alkaloids and their potential as antimicrobial and anticancer agents. Toxicol. Vitro, 14: 53-59, 2000.
6. Staerk, D., Lykkeberg, A. K., Christensen, J., Budnik, B. A., Abe, F., and Jaroszewski, J. W. In vitro cytotoxicity activity of phenanthroindolizidine alkaloids from Cynanchum vincetoxicum and Tylophora tanakae against drug-sensitive and multidrug-resistant cancer cells. J. Nat. Prod., 65: 1299-1302, 2002.
7. Ganguly, T., and Khar. A. Induction of apoptosis in a human erythroleukemic cell line K562 by tylophora alkaloids involves release of cytochrome c and activation of caspase 3. Phytomedicine, 9: 288-295, 2002.
8. Komatsu, H., Watanabe, M., Ohyama, M., Enya, T., Koyama, K., Kanazawa, T., Kawahara, N., Sugimura, T., and Wakabayashi, K. Phenanthroindolizidine alkaloids as cytotoxic substances in a Danaid butterfly, Ideopsis similis, against human cancer cells. J. Med. Chem., 44: 1833-1836, 2001.
9. Paull, K. D., Hamel, E., and Malspeis, L. Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute. In: W. O. Foye (ed.), Cancer Chemotherapeutic Agents, pp. 9-45. Washington, DC: American Chemical Society, 1995.
10. El-Serag, H. B., and Mason, A. C. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med., 340: 745-750, 1999.
11. McCaughan, G. W., Koorey, D. J., and Strasser, S. 1. Hepatocellular carcinoma: current approaches to diagnosis and management. Intern. Med. J., 32: 394-400, 2002.
12. Juliano, R. L., and Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta. 455: 152-162, 1976.
13. Gerlach, J. H., Endicott, J. A., Juranka, P. F., Henderson, G., Sarangi, F., Deuchars, K. L., and Ling, V. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature (Lond.), 324: 485-489, 1986.
14. Cole, S. P., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M., and Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Wash. DC), 258: 1650-1654, 1992.
15. Xu, Y., and Villalona-Calero, M. A. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann. Oncol., 13: 1841-1851, 2002.
16. Beck, W. T., Morgan, S. E., Mo, Y. Y., and Bhat, U. G. Tumor cell resistance to DNA topoisomerase II inhibitors: new developments. Drug Resist. Updat., 2: 382-389, 1999.
17. Wang, C. Y., Cusack, J. C., Jr., Liu, R., and Baldwin, A. S., Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat. Med., 5: 412-417, 1999.
18. Cusack, J. C., Jr., Liu, R., and Baldwin, A. S., Jr. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB activation. Cancer Res., 60: 2323-2330, 2000.
19. Manley, P. W., Cowan-Jacob, S. W., Buchdunger, E., Fabbro, D., Fendrich, G., Furet, P., Meyer, T., and Zimmermann, J. Imatinib: a selective tyrosine kinase inhibitor. Eur. J. Cancer, 38: S19-S27, 2002.
20. Gilmore, T., Gapuzan, M. E., Kalaitzidis, D., and Starczynowski, D. Rel/NF-κB/IκB signal transduction in the generation and treatment of human cancer. Cancer Lett., 181: 1-9, 2002.
21. Sen, R., and Baltimore, D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 46: 705-716, 1986.
22. Bharti, A. C., and Aggarwal, B. B. Nuclear factor-κB and cancer: its role in prevention and therapy. Biochem. Pharmacol., 64: 883-888, 2002.
23. Mitchell, B. S. The proteasome-an emerging therapeutic target in cancer. N. Engl. J. Med., 348: 2597-2598, 2003.
24. Chen, H. X., Bamberger, U., Heckel, A., Guo. X., and Cheng, Y. C. BIBW 22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport. Cancer Res. 53: 1974-1977, 1993.
25. Ferguson, P. J., Fisher, M. H., Stephenson, J., Li, D. H., Zhou, B. S., and Cheng, Y. C. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res., 48: 5956-5964, 1988.
26. Gaj, C. L., Anyanwutaku, I., Chang, Y. H., and Cheng, Y. C. Decreased drug accumulation without increased drug efflux in a novel. MRP-overexpressing multidrug-resistant cell line. Biochem. Pharmacol., 55: 1199-1211, 1998.
27. Yen, Y., Grill, S. P., Dutschman, G. E., Chang, C. N., Zhou, B. S., and Cheng, Y. C. Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. Cancer Res., 54: 3686-3691, 1994.
28. Beidler, D. R., Chang, J. Y., Zhou, B. S., and Cheng, Y. C. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res., 56: 345-353, 1996.
29. Park, S. Y., Lam, W., and Cheng, Y. C. X-ray repair cross-complementing gene 1 protein plays an important role in camptothecin resistance. Cancer Res., 62: 459-465, 2002.
30. Finlay, G. J., Baguley, B. C., and Wilson, W. R. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal. Biochem., 139: 272-277, 1984.
31. Buckley, T. F., and Rapoport, H. α-Amino acids as chiral educts for asymmetric products. Chirally specific syntheses of tylophorine and cryptopleurine. J. Org. Chem., 48: 4222-4232, 1983.
32. Hollingshead, M. G., Alley, M. C., Camalier, R. F., Abbott, B. J., Mayo, J. G., Malspeis, L., and Grever, M. R. In vivo cultivation of tumor cells in hollow fibers. Life Sci., 57: 131-141, 1995.
33. Plowman, J., Dykes, D. J., Hollingshead, M., Simpson-Herren, L., and Alley, M. C. Human tumor xenograft models in NCI drug development. In: B. Teicher (ed), Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, pp. 101-125. Totowa, NJ: Humana Press, 1997.
34. Lakin, N. D., and Jackson, S. P. Regulation of p53 in response to DNA damage. Oncogene, 18: 7644-7655, 1999.
35. Milner, J. DNA damage, p53 and anticancer therapies. Nat. Med., 1: 879-880, 1995.
36. Wahl, G. M., and Carr, A. M. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat. Cell. Biol., 3: E277-E286, 2001.
37. Tai, D. I., Tsai, S. L., Chang, Y. H., Huang, S. N., Chen, T. C., Chang, K. S., and Liaw, Y. F. Constitutive activation of nuclear factor κB in hepatocellular carcinoma. Cancer (Phila.), 89: 2274-2281, 2000.
38. Govindachari, T. R., Lakshmikantham, M. V., and Rajadurai, S. Synthesis of (+/-)-tylophorine. Chem. Ind. (Lond.), 23: 664-664, 1960.
39. Darnell, J. E., Jr. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer, 2: 740-749, 2002.
40. Shaulian, E., and Karin, M. AP-1 as a regulator of cell life and death. Nat. Cell Biol., 4: E131-E136, 2002.